New York is currently home to 4451 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Recruiting
This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Memorial Sloan Kettering Commack (All protocol activities), Commack, New York
Conditions: Metastatic Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
Recruiting
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/05/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail PF
Recruiting
This investigation is a prospective, multicenter clinical investigation. It is anticipated that a total of 50 subjects will be enrolled at up to 5 sites. Enrollment is estimated to commence in Q4 of 2018. Neither subjects nor investigators are blinded to treatment and the clinical investigation includes a historical control which will be compared to the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System. Total duration of enrollment, 12 month follow-up and analysis is expected... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Ariana Meltzer-Bruhn, New York, New York
Conditions: Femoral Fracture
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Recruiting
The study will enroll patients with prior IO therapy (alone or in combination with chemotherapy or in combination with other IO agents) regardless of the PD-L1 level, into a non-randomized combination trial, with primary endpoint of disease control rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: NYU Langone, New York, New York
Conditions: Non Small Cell Lung Cancer
Functional Assessment in Liver Transplantation
Recruiting
This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disability using functional status measures at baseline and at every clinic visit in the pre-transplant setting. Subjects will also answer questions regarding quality of life, personality, and/or cognitive function. Subjects will again undergo assessments at every clinic visit through 12 months after transplant. Then, they will be followed annuall... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Columbia University, New York, New York
Conditions: End Stage Liver Disease
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Recruiting
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Hospital for Special Surgery, New York, New York
Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Early Age-Related Hearing Loss Investigation (EARHLI)
Recruiting
Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention. Participants will be followed for 1 year. This study will provide information on reducing cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD).
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
06/04/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Alzheimer Disease, Hearing Loss, Cognitive Impairment
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting
The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. This type of treatment approach is called total neoadjuvant therapy (TNT). The researchers will also look at whether the sequence of the treatme... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York
Conditions: Pancreatic Ductal Adenocarcinoma
Pembrolizumab for Advanced NSCLC and PS 2-3
Recruiting
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radiation. Patients will be eligible for the trial if ISMMS reviewed samples from tumor biopsy have a PDL-1 TPS ≥ 1% and have ECOG performance status rated 2 or 3. All patients will receive anti PD-1 therapy with pembrolizumab 200mg IV ev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Mount Sinai Hospital, New York, New York
Conditions: Non-Small Cell Lung Cancer (NSCLC)
Delivering Empowering Conversations About Obstetric Regional Anesthesia for Underserved Minorities
Recruiting
Racial and ethnic disparities in obstetric anesthesia care remains persistent despite studies documenting its existence and calling for action. The goal of this study is to share disparity data with underserved minority groups being admitted to the labor and delivery unit for obstetric care, to reduce mistrust and misconceptions regarding obstetric anesthesia care, and to bridge the cultural gap between patient beliefs and safe anesthetic care and to empower patients through transparency and pro... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: The Mount Sinai Hospital, New York, New York
Conditions: Postpartum Recovery
Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging
Recruiting
The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future could identify the sentinel lymph nodes and only remove these instead of removing all the lymph nodes which is currently done.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Esophageal Cancer
Recovery of Consciousness Following Intracerebral Hemorrhage
Recruiting
The objectives of the RECONFIG clinical study are to : 1. To identify the time to the first diagnosis of cognitive motor dissociation (CMD) in intracerebral hemorrhage (ICH) patients and to investigate whether these patients will clinically follow commands earlier after the hemorrhage. 2. To determine whether CMD independently predicts long term functional outcomes (6-month mRS scores) in ICH patients, and is associated with long term cognitive and quality of life outcomes. 3. To determine the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Intra Cerebral Hemorrhage